PL3600276T3 - Betahistyna lub jej farmaceutycznie dopuszczalna sól oraz inhibitor monoaminooksydazy do stosowania w leczeniu lub zapobieganiu jednemu lub większej liczbie objawów zawrotów głowy u osobnika - Google Patents

Betahistyna lub jej farmaceutycznie dopuszczalna sól oraz inhibitor monoaminooksydazy do stosowania w leczeniu lub zapobieganiu jednemu lub większej liczbie objawów zawrotów głowy u osobnika

Info

Publication number
PL3600276T3
PL3600276T3 PL18715909.0T PL18715909T PL3600276T3 PL 3600276 T3 PL3600276 T3 PL 3600276T3 PL 18715909 T PL18715909 T PL 18715909T PL 3600276 T3 PL3600276 T3 PL 3600276T3
Authority
PL
Poland
Prior art keywords
betahistine
vertigo
symptoms
prevention
subject
Prior art date
Application number
PL18715909.0T
Other languages
English (en)
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1704949.5A external-priority patent/GB201704949D0/en
Priority claimed from GBGB1711677.3A external-priority patent/GB201711677D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of PL3600276T3 publication Critical patent/PL3600276T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18715909.0T 2017-03-28 2018-03-28 Betahistyna lub jej farmaceutycznie dopuszczalna sól oraz inhibitor monoaminooksydazy do stosowania w leczeniu lub zapobieganiu jednemu lub większej liczbie objawów zawrotów głowy u osobnika PL3600276T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1704949.5A GB201704949D0 (en) 2017-03-28 2017-03-28 Combination treatment
GBGB1711677.3A GB201711677D0 (en) 2017-07-20 2017-07-20 Combination treatment
PCT/GB2018/050822 WO2018178670A1 (en) 2017-03-28 2018-03-28 Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject

Publications (1)

Publication Number Publication Date
PL3600276T3 true PL3600276T3 (pl) 2023-08-21

Family

ID=61906770

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18715909.0T PL3600276T3 (pl) 2017-03-28 2018-03-28 Betahistyna lub jej farmaceutycznie dopuszczalna sól oraz inhibitor monoaminooksydazy do stosowania w leczeniu lub zapobieganiu jednemu lub większej liczbie objawów zawrotów głowy u osobnika

Country Status (13)

Country Link
US (3) US11083718B2 (pl)
EP (2) EP3600276B1 (pl)
DK (1) DK3600276T3 (pl)
ES (1) ES2950452T3 (pl)
FI (1) FI3600276T3 (pl)
HR (1) HRP20230735T1 (pl)
HU (1) HUE062729T2 (pl)
LT (1) LT3600276T (pl)
PL (1) PL3600276T3 (pl)
PT (1) PT3600276T (pl)
RS (1) RS64304B1 (pl)
SI (1) SI3600276T1 (pl)
WO (1) WO2018178670A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3600276T3 (da) 2017-03-28 2023-07-10 Intrabio Ltd Betahistin, eller et farmaceutisk acceptabelt salt deraf og en monoaminoxidase-inhibitor til anvendlese til behandling eller forebyggelse af et eller flere symptomer på svimmelhed hos et individ
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7728015B2 (en) 2004-04-22 2010-06-01 Mor Research Applications Ltd. Compositions for weight management
NZ589742A (en) * 2008-05-27 2012-06-29 Univ Melbourne Methods of treating mammals with eustachian tube dysfunctions with betahistine
EP2491930A1 (en) * 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
DK3600276T3 (da) 2017-03-28 2023-07-10 Intrabio Ltd Betahistin, eller et farmaceutisk acceptabelt salt deraf og en monoaminoxidase-inhibitor til anvendlese til behandling eller forebyggelse af et eller flere symptomer på svimmelhed hos et individ

Also Published As

Publication number Publication date
US20230285373A1 (en) 2023-09-14
HRP20230735T1 (hr) 2023-10-13
EP3600276A1 (en) 2020-02-05
EP4234022A2 (en) 2023-08-30
SI3600276T1 (sl) 2023-08-31
US20210085659A1 (en) 2021-03-25
US20210361632A1 (en) 2021-11-25
EP4234022A3 (en) 2023-10-04
US11690830B2 (en) 2023-07-04
PT3600276T (pt) 2023-07-11
RS64304B1 (sr) 2023-07-31
US11083718B2 (en) 2021-08-10
LT3600276T (lt) 2023-08-10
EP3600276B1 (en) 2023-05-31
HUE062729T2 (hu) 2023-12-28
FI3600276T3 (fi) 2023-06-29
DK3600276T3 (da) 2023-07-10
WO2018178670A1 (en) 2018-10-04
ES2950452T3 (es) 2023-10-10

Similar Documents

Publication Publication Date Title
IL288231A (en) An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts.
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
IL282487A (en) TYK2 inhibitors and their use
SG11202013231SA (en) HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
IL268327A (en) A pharmaceutical preparation for use in the treatment and prevention of c5-related diseases and methods for the treatment and prevention of c5-related diseases
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
IL283409A (en) tyk2 inhibitors and uses thereof
IL282090A (en) tyk2 inhibitors and uses thereof
MX2021010886A (es) Uso de medicamentos para disminuir la evolucion de la enfermedad de parkinson.
EP3431517A4 (en) Copolymer and surface treatment
IL271728A (en) Materials, uses and treatment methods
MX2016014699A (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
EP3541185C0 (en) USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION
IL273922A (en) D-amino acid oxidase inhibitors and their therapeutic uses
SI3600276T1 (sl) Betahistin ali njegova farmacevtsko sprejemljiva sol in inhibitor monoaminoksidaze, za uporabo pri zdravljenju ali preprečevanju enega ali več simptomov vrtoglavice pri subjektu
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
NZ733451A (en) Combination therapy for pulmonary hypertension
HK1247917A1 (zh) 與金屬和/或自由基螯合構型有關的鄰伯二胺，及其抗羰基和氧化應激的活性，及其用途
WO2016126572A3 (en) Glucosylceramide synthase inhibitors and therapeutic methods using the same
GB201519258D0 (en) Newly identified wnt/beta-catenin signal transduction inhibitors and the use thereof in the treatment or prevention of diseases and conditions.
MX2018012587A (es) (+)-azasetron para uso en el tratamiento de trastornos del oido.
IL247616B (en) Centrally acting acetylcholinesterase inhibitors for the prevention/or treatment of chemically induced neurodegenerative diseases and their symptoms, and corresponding compositions, uses, methods and kit
HUE052035T2 (hu) Legalább egy proteáz ihibitor és dexpantenol kombinációja bõrsérülések megelõzésében és/vagy kezelésében történõ alkalmazásra
IL290328A (en) Monoamine oxidase b inhibitors for use in the prevention or treatment of prostate cancer
PH12018500221A1 (en) A prolonged release dosage form comprising oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof in the treatment of bladder pain syndrome (bps)